

Transforming Gynecologic Health

Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. Current products include OvaWatch® and Ova1Plus® which are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year.

Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.

Investment Highlights

- Revenue-generating company with a portfolio of proprietary risk assessment assays targeting ovarian cancer, collectively called OvaSuite
- Experienced management team with proven track record of success
- Broad managed care coverage (Ova1Plus® and OvaWatchSM Medicare reimbursement - \$897)
- Strong IP and technology protection
- Transformative in-development test pipeline including EndoCheck, EndoMDxSM, and OvaMDxSM and expansion of OvaWatch for longitudinal monitoring

Our OvaSuite Products



OvaWatch, a lab-developed test performed on an FDA approved platform with a 99% Negative Predictive Value, assists in the initial clinical assessment of ovarian malignancy risk in patients with adnexal masses not planned for surgical intervention.



Ova1Plus is a reflex process of two FDA-cleared blood tests, Ova1®, and Overa®, to assess risk of ovarian malignancy in women with adnexal masses planned for surgery.

Recent Developments

18 Mar 2024

AWH Expands SLT with the Addition of Sandra Milligan, M.D., J.D. as President

12 Feb 2024

AWH Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)

6 Feb 2024

AWH Announces OvaSuiteSM Distribution Agreement in the Philippines

25 Jan 2024

AWH Announces \$5.5 Million Registered Direct Offering and Concurrent Private Placement

19 Dec 2023

AWH to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

6 Dec 2023

AWH Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Fast Facts

Ticker (Exchange) AWH (NASDAQ)

Stock Price \$4.08
(as of 12/29/23)

Market Cap \$43.4M
(as of 12/31/23)

Outstanding Shares 10.6M
(as of 12/31/23)

52-Week Range \$2.31-9.60

Avg. Daily Volume 41,411

Headquarters Austin, TX

Fiscal Year End December 31

Cash* Available \$2.9M
(as of 12/31/23)

Product Revenues	4Q23	FY2023
In Millions	\$2.1	\$9.2
YoY Growth	2%	15%

*incl cash, cash equivalents and restricted cash

Equity Coverage Analysts

William Blair **Alliance Global Partners**
Andrew Brackmann, CFA Ben Haynor, CFA

Water Tower Research **Cantor Fitzgerald**
Sally Yanchus Ross Osborn, CFA

Executive Officers

Nicole Sandford
CEO & Board Member

Dr. Torsten Hombeck
Chief Financial Officer



**Visit Aspira's investor relations webpage to
view our recent R&D Day Presentation.**

Contact Us:

investor@aspirawh.com

Aspira Women's Health, Inc.

Corporate Headquarters

3 Enterprise Drive, #220

Shelton CT, 06484

Phone: (844) 277-4721

www.aspirawh.com
